Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Assets (2019 - 2025)

Allogene Therapeutics' Return on Assets history spans 7 years, with the latest figure at 0.46% for Q3 2025.

  • For Q3 2025, Return on Assets fell 2.0% year-over-year to 0.46%; the TTM value through Sep 2025 reached 0.46%, down 2.0%, while the annual FY2024 figure was 0.43%, 1.0% up from the prior year.
  • Return on Assets for Q3 2025 was 0.46% at Allogene Therapeutics, up from 0.48% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.17% in Q4 2021 and bottomed at 0.48% in Q2 2025.
  • The 5-year median for Return on Assets is 0.44% (2024), against an average of 0.36%.
  • The largest annual shift saw Return on Assets grew 10bps in 2021 before it decreased -23bps in 2023.
  • A 5-year view of Return on Assets shows it stood at 0.17% in 2021, then plummeted by -131bps to 0.39% in 2022, then dropped by -19bps to 0.46% in 2023, then rose by 4bps to 0.45% in 2024, then dropped by -3bps to 0.46% in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Return on Assets are 0.46% (Q3 2025), 0.48% (Q2 2025), and 0.47% (Q1 2025).